Abstract
Retisert (Envision TD), a sustained release intraocular implant containing fluocinolone acetonide, has been developed and launched in the US by Bausch & Lomb and Control Delivery Systems for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1159-1167 |
| Number of pages | 9 |
| Journal | Current Opinion in Investigational Drugs |
| Volume | 6 |
| Issue number | 11 |
| State | Published - Nov 2005 |
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery